Verve Therapeutics Inc (NASDAQ: VERV) kicked off on Friday, up 3.49% from the previous trading day, before settling in for the closing price of $5.73. Over the past 52 weeks, VERV has traded in a range of $4.30-$20.12.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Over the past five-year period, the growth rate of yearbook sales for the company of the Healthcare sector was 126.44%. While this was happening, its average annual earnings per share was recorded 17.45%. With a float of $62.47 million, this company’s outstanding shares have now reached $81.97 million.
Considering the fact that the conglomerate employs 255 people, you should pay attention to its efficiency factor. In terms of profitability, gross margin is 61.18%, operating margin of -1075.0%, and the pretax margin is -931.71%.
Verve Therapeutics Inc (VERV) Insider Activity
Our next focus will be how large-scale investors are participating in this stock of the Biotechnology Industry. The insider ownership of Verve Therapeutics Inc is 26.18%, while institutional ownership is 66.64%. The most recent insider transaction that took place on May 14 ’24, was worth 475,760. In this transaction an insider of this company bought 76,000 shares at a rate of $6.26, taking the stock ownership to the 342,509 shares. Before that another transaction happened on Apr 02 ’24, when Company’s Chief Administrative Officer sold 1,514 for $8.24, making the entire transaction worth $12,475. This insider now owns 8,659 shares in total.
Verve Therapeutics Inc (VERV) Earnings and Forecasts
According to the Wall Street analysts, stocks earnings will be around 17.45% per share during the next fiscal year.
Verve Therapeutics Inc (NASDAQ: VERV) Trading Performance Indicators
Take a look at Verve Therapeutics Inc’s (VERV) current performance indicators. Last quarter, stock had a quick ratio of 14.64. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 25.15.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -2.60, a number that is poised to hit -0.68 in the next quarter and is forecasted to reach -2.87 in one year’s time.
Technical Analysis of Verve Therapeutics Inc (VERV)
Compared to the last year’s volume of 1.31 million, its volume of 1.22 million showed lagged in the last five days. As of the previous 9 days, the stock’s Stochastic %D was 44.93%. Additionally, its Average True Range was 0.36.
During the past 100 days, Verve Therapeutics Inc’s (VERV) raw stochastic average was set at 44.46%, which indicates a significant decrease from 65.62% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 56.53% in the past 14 days, which was lower than the 72.96% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $5.40, while its 200-day Moving Average is $7.73. Nevertheless, the first resistance level for the watch stands at $6.04 in the near term. At $6.15, the stock is likely to face the second major resistance level. The third major resistance level sits at $6.34. If the price goes on to break the first support level at $5.74, it is likely to go to the next support level at $5.54. Should the price break the second support level, the third support level stands at $5.43.
Verve Therapeutics Inc (NASDAQ: VERV) Key Stats
The company with the Market Capitalisation of 519.34 million has total of 84,625K Shares Outstanding. Its annual sales at the moment are 11,760 K in contrast with the sum of -200,070 K annual income. Company’s last quarter sales were recorded 6,690 K and last quarter income was -49,810 K.
